Approved Ataxia Drug Repurposed to Degrade STING via 'Molecular Crowbar'
- Omaveloxolone is an FDA-approved Nrf2-activating drug, originally approved for Friedreich's ataxia, now repurposed as a STING-targeting agent.
- It binds the base of STING's ligand-binding domain, destabilizing the protein's folded structure.
- This triggers K27-linked polyubiquitination of STING and its subsequent degradation by the proteasome — a "molecular crowbar" mechanism.
- Unlike classical PROTAC-style bifunctional degraders, omaveloxolone acts as a single small molecule, directly destabilizing STING rather than using a ligand-linker-E3-ligase construct.
- In aged mice, omaveloxolone treatment reduced STING-pathway-driven inflammation, a hallmark of age-related "inflammaging."
A monovalent degrader that's neither a classic PROTAC nor a molecular glue — that's the interesting bit. "Molecular crowbar" reads like marketing, but mechanistically it sounds like ligand-induced conformational destabilization exposing a degron: closer to hydrophobic-tag logic than E3-recruitment chemistry, no linker or ternary-complex engineering required. Chemically elegant, if it holds up. The real draw is that omaveloxolone's safety and PK are already banked — repurposing means skipping a decade of tox work if this translates. But my triage instinct says this is serendipitous polypharmacology, not designed SAR; the Nrf2 pharmacophore was never built for STING's pocket. It's also secondary-sourced with no primary structural data yet — I'd want a co-crystal or HDX-MS confirming direct engagement before trusting the crowbar story over generic proteostasis stress.